Citius Pharma FY26 Q3 net loss narrows to $8.9 million; revenue turns to $1.5 million

Citius Pharmaceuticals posted revenue of $1.49 million for the quarter, versus no revenue a year earlier.

Net loss applicable to common stockholders narrowed to $8.86 million, or $0.34 per share, from $8.79 million, or $0.80.

Cash and cash equivalents rose to $17.01 million at June 30, 2026, from $4.25 million at Sept. 30, 2025.

LYMPHIR became available at 44 institutions; institutional vial orders from wholesalers rose 31% as new ordering institutions increased 80%.

Management said near-universal payer coverage has been secured, with no reimbursement denials or preauthorization barriers reported to date.